Voriconazole Dosing and Management for Invasive Aspergillosis
For adults with invasive Aspergillus infection, initiate voriconazole with a loading dose of 6 mg/kg IV every 12 hours for two doses on day 1, followed by a maintenance dose of 4 mg/kg IV every 12 hours, with transition to oral therapy at 200 mg every 12 hours once clinically improved. 1
Standard Dosing Regimen
Loading and Maintenance Doses
- Loading dose: 6 mg/kg IV every 12 hours for the first 24 hours (two doses total)
- IV maintenance: 4 mg/kg IV every 12 hours
- Oral maintenance: 200 mg every 12 hours after clinical improvement 2, 3, 1
The oral 200 mg dose achieves exposure similar to 3 mg/kg IV, while 300 mg oral achieves exposure similar to 4 mg/kg IV 1. Continue IV therapy for at least 7 days before switching to oral formulation 3, 1.
Dose Adjustments Based on Response
If inadequate clinical response occurs:
- Increase oral maintenance from 200 mg to 300 mg every 12 hours
- For patients <40 kg: increase from 100 mg to 150 mg every 12 hours
- If unable to tolerate higher doses, reduce by 50 mg increments to minimum of 200 mg every 12 hours 1
For Aspergillus flavus and Aspergillus terreus, higher dosages are recommended compared to Aspergillus fumigatus 2.
Therapeutic Drug Monitoring (TDM)
TDM is strongly recommended with target trough concentrations of 1-5 μg/mL for efficacy while minimizing toxicity 4. Most experts aim for:
- Efficacy threshold: >1-1.5 μg/mL
- Toxicity threshold: <5-6 μg/mL 4
When TDM is Critical
TDM becomes essential in these situations 4:
- Impaired gastrointestinal function or hepatic disease
- Pediatric, elderly, obese, or critically ill patients
- Concomitant medications affecting CYP3A4, CYP2C19, or CYP2C9
- CNS or disseminated aspergillosis (severe disease)
- Suspected breakthrough infection
- Suspected drug toxicity, particularly neurotoxicity
- Compliance concerns during long-term therapy
A prospective trial demonstrated that TDM reduced voriconazole discontinuation due to adverse events (4% vs 17%, P=0.02) and improved response rates (81% vs 57%, P=0.04) 4.
Hepatic Impairment
In mild to moderate hepatic impairment (Child-Pugh Class A and B), use half the standard maintenance dose 1. No adjustment needed for loading dose 3.
For severe hepatic impairment (Child-Pugh Class C), voriconazole use has not been adequately studied, but extreme caution is warranted given extensive hepatic metabolism 3.
Renal Impairment
Avoid IV voriconazole in patients with creatinine clearance <50 mL/min due to accumulation of the cyclodextrin vehicle 3, 1. The oral formulation does not contain cyclodextrin and can be used without dose adjustment in renal impairment 3, 1.
While some retrospective data suggest IV use may be acceptable in renal dysfunction without identified toxicity, the official recommendation remains to avoid IV administration in moderate to severe renal impairment 5.
Drug Interactions
Contraindicated Combinations
Voriconazole is absolutely contraindicated with 1:
- CYP3A4 substrates: Cisapride, pimozide, quinidine (risk of QT prolongation and torsades)
- CYP3A4 inducers: Rifampin, carbamazepine, long-acting barbiturates, rifabutin, St. John's Wort (loss of voriconazole efficacy)
- Other: Sirolimus, ergot alkaloids, efavirenz (standard dose), ritonavir, naloxegol, tolvaptan
Critical Dose Adjustments for Drug Interactions
When coadministered with phenytoin: Increase voriconazole maintenance to 5 mg/kg IV every 12 hours or 400 mg oral every 12 hours 3, 1
When coadministered with efavirenz (if unavoidable): Increase voriconazole to 400 mg every 12 hours and decrease efavirenz to 300 mg once daily 3
Be aware of interactions with anticonvulsants in CNS aspergillosis, as both therapeutic classes affect each other's metabolism 2, 3.
Voriconazole significantly increases levels of immunosuppressants (cyclosporine, tacrolimus, sirolimus), requiring dose reductions of these agents 6.
Pregnancy and Contraception
Voriconazole is contraindicated in pregnancy due to teratogenic effects demonstrated in animal studies 1. It can cause fetal harm when administered to pregnant women 1.
Advise females of reproductive potential to use effective contraception during voriconazole treatment 1. The risk-benefit assessment must be carefully considered, as invasive aspergillosis carries high mortality.
Site-Specific Considerations
CNS Aspergillosis
Voriconazole is the preferred agent due to excellent CSF penetration (>50% of serum concentration) 3, 5. Surgical resection should be pursued if feasible, and combination therapy with an echinocandin may be considered 2.
Endocarditis
Early surgical intervention is critical to prevent embolic complications 2. Post-operative lifelong antifungal therapy with frequent monitoring is recommended 2.
Duration of Therapy
Treat invasive pulmonary aspergillosis until resolution or stabilization of all clinical and radiographic manifestations 3. In the pivotal trial, median IV therapy duration was 10 days (range 2-85), with median oral therapy of 76 days (range 2-232) 3.
Continue therapy throughout the period of immunosuppression and until lesions have resolved 3. For successfully treated patients requiring subsequent immunosuppression, resumption of antifungal prophylaxis prevents recurrent infection 3.
Monitoring Parameters
Clinical and Laboratory Monitoring
- Liver function tests: At baseline and regularly during therapy, as hepatotoxicity is a serious risk 1
- Visual function: If treatment exceeds 28 days, monitor for optic neuritis and papilledema 1
- Electrolytes: Correct potassium, magnesium, and calcium before initiating therapy to minimize QT prolongation risk 1
- ECG monitoring: In patients with proarrhythmic conditions 1
Radiographic Monitoring
Serial CT imaging at individualized intervals based on clinical acuity 3. Note that pulmonary infiltrate volume may increase during the first 7-10 days of therapy, especially with granulocyte recovery 3.
Common Pitfalls
Visual disturbances occur in ~30% of patients but are typically transient and reversible 3, 7. These should not prompt discontinuation unless severe.
Photosensitivity is significant—instruct patients to avoid direct sunlight and use sun protection 1.
Adrenal dysfunction can occur when voriconazole is combined with corticosteroids. Monitor for both Cushing's syndrome and adrenal insufficiency during and after treatment 1.
Long-term therapy (>6 months) carries risk of fluorosis and periostitis—discontinue if skeletal adverse reactions occur 1.
CYP2C19 polymorphisms cause significant interpatient variability. Asian populations have higher frequencies of slow metabolizer phenotypes, potentially requiring dose adjustments 3.
Oral voriconazole must be taken at least 1 hour before or after meals to ensure adequate absorption 1.